NO20075461L - Neurotrypsin inhibitorer - Google Patents
Neurotrypsin inhibitorerInfo
- Publication number
- NO20075461L NO20075461L NO20075461A NO20075461A NO20075461L NO 20075461 L NO20075461 L NO 20075461L NO 20075461 A NO20075461 A NO 20075461A NO 20075461 A NO20075461 A NO 20075461A NO 20075461 L NO20075461 L NO 20075461L
- Authority
- NO
- Norway
- Prior art keywords
- neurotrypsin
- agrin
- fragment
- variant
- compound
- Prior art date
Links
- 102100035484 Neurotrypsin Human genes 0.000 title abstract 3
- 108010037733 neurotrypsin Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 101150079978 AGRN gene Proteins 0.000 abstract 3
- 102100040026 Agrin Human genes 0.000 abstract 3
- 108700019743 Agrin Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 abstract 1
- 229940100584 Neurotrypsin inhibitor Drugs 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 abstract 1
- 239000012062 aqueous buffer Substances 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229940028332 halog Drugs 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000025185 skeletal muscle atrophy Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/976—Trypsin; Chymotrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102481 | 2005-03-30 | ||
| PCT/EP2006/061152 WO2006103261A2 (en) | 2005-03-30 | 2006-03-29 | Inhibitors of neurotrypsin and determination thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075461L true NO20075461L (no) | 2007-11-20 |
Family
ID=34939082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075461A NO20075461L (no) | 2005-03-30 | 2007-10-29 | Neurotrypsin inhibitorer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7897364B2 (https=) |
| EP (1) | EP1868989A2 (https=) |
| JP (1) | JP4920675B2 (https=) |
| KR (1) | KR20070116932A (https=) |
| CN (1) | CN101193858B (https=) |
| AU (1) | AU2006228150B2 (https=) |
| BR (1) | BRPI0609654A2 (https=) |
| CA (1) | CA2600791A1 (https=) |
| IL (1) | IL186120A (https=) |
| MX (1) | MX2007011961A (https=) |
| NO (1) | NO20075461L (https=) |
| NZ (1) | NZ562796A (https=) |
| RU (1) | RU2424228C2 (https=) |
| WO (1) | WO2006103261A2 (https=) |
| ZA (1) | ZA200707359B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008074813A2 (en) * | 2006-12-21 | 2008-06-26 | Neurotune Ag | Optiogenin for the treatment of neural diseases |
| PL1990420T3 (pl) * | 2007-05-10 | 2011-01-31 | Neurotune Ag | Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną |
| EP2295068A1 (en) * | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| EP2635559A2 (en) | 2010-11-01 | 2013-09-11 | Neurotune AG | Neurotrypsin inhibitors |
| WO2012059443A2 (en) | 2010-11-01 | 2012-05-10 | Neurotune Ag | Novel neurotrypsin inhibitors |
| EP2631657A1 (en) * | 2012-02-25 | 2013-08-28 | Neurotune AG | Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH692507A5 (de) * | 1997-04-26 | 2002-07-15 | Peter Prof Dr Sonderegger | Neurotrypsin als aktive Verbindung in einem Medikament. |
| DE19919634C2 (de) * | 1999-04-30 | 2001-06-07 | Aventis Pharma Gmbh | Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen |
| DE10247478A1 (de) * | 2002-10-11 | 2004-06-24 | Bioagency Ag | Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen |
-
2006
- 2006-03-29 WO PCT/EP2006/061152 patent/WO2006103261A2/en not_active Ceased
- 2006-03-29 RU RU2007139754/04A patent/RU2424228C2/ru not_active IP Right Cessation
- 2006-03-29 AU AU2006228150A patent/AU2006228150B2/en not_active Ceased
- 2006-03-29 JP JP2008503516A patent/JP4920675B2/ja not_active Expired - Fee Related
- 2006-03-29 KR KR1020077024937A patent/KR20070116932A/ko not_active Withdrawn
- 2006-03-29 US US11/887,136 patent/US7897364B2/en not_active Expired - Fee Related
- 2006-03-29 CA CA002600791A patent/CA2600791A1/en not_active Abandoned
- 2006-03-29 CN CN2006800101171A patent/CN101193858B/zh not_active Expired - Fee Related
- 2006-03-29 MX MX2007011961A patent/MX2007011961A/es not_active Application Discontinuation
- 2006-03-29 NZ NZ562796A patent/NZ562796A/en not_active IP Right Cessation
- 2006-03-29 BR BRPI0609654-9A patent/BRPI0609654A2/pt not_active IP Right Cessation
- 2006-03-29 EP EP06725408A patent/EP1868989A2/en not_active Withdrawn
-
2007
- 2007-08-29 ZA ZA200707359A patent/ZA200707359B/xx unknown
- 2007-09-20 IL IL186120A patent/IL186120A/en not_active IP Right Cessation
- 2007-10-29 NO NO20075461A patent/NO20075461L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4920675B2 (ja) | 2012-04-18 |
| EP1868989A2 (en) | 2007-12-26 |
| KR20070116932A (ko) | 2007-12-11 |
| WO2006103261A9 (en) | 2010-05-27 |
| CN101193858A (zh) | 2008-06-04 |
| CA2600791A1 (en) | 2006-10-05 |
| JP2008538178A (ja) | 2008-10-16 |
| RU2424228C2 (ru) | 2011-07-20 |
| WO2006103261A3 (en) | 2007-02-22 |
| IL186120A (en) | 2012-08-30 |
| AU2006228150A1 (en) | 2006-10-05 |
| RU2007139754A (ru) | 2009-05-10 |
| WO2006103261A2 (en) | 2006-10-05 |
| AU2006228150B2 (en) | 2011-09-29 |
| US7897364B2 (en) | 2011-03-01 |
| US20090170950A1 (en) | 2009-07-02 |
| ZA200707359B (en) | 2009-08-26 |
| IL186120A0 (en) | 2008-01-20 |
| BRPI0609654A2 (pt) | 2010-04-20 |
| MX2007011961A (es) | 2008-03-14 |
| CN101193858B (zh) | 2012-01-04 |
| NZ562796A (en) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075461L (no) | Neurotrypsin inhibitorer | |
| IS2549B (is) | Kaþepsín systein próteasa hindrar | |
| GEP20125683B (en) | Serine proteases inhibitors for hcv infections treatment | |
| WO2007016476A3 (en) | Hepatitis c serine protease inhibitors and uses therefor | |
| ATE409482T1 (de) | Cathepsincystein-proteasehemmer | |
| NO20052096L (no) | Fremgangsmater for a danne og screene for proteaser med endret spesifisitet. | |
| NO20052690L (no) | Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke. | |
| CY1108146T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ | |
| NO20076554L (no) | Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer | |
| CY1110214T1 (el) | Μεθοδοι και ενδιαμεσα | |
| Prusis et al. | Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B–NS3 proteases | |
| WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
| DK1680507T3 (da) | Bakterieekspression af proteaseinhibitorer og varianter deraf | |
| DE602004026440D1 (de) | Kondensierte indole als dipeptidyl-peptidase-hemmer zur behandlung oder prävention von diabetes | |
| BR0316583A (pt) | Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
| SE0201976D0 (sv) | Novel compounds | |
| ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
| ATE423122T1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
| TW200631576A (en) | Cathepsin cysteine protease inhibitors | |
| IS7928A (is) | Sertakónasóllyfjablöndur til notkunar í leggöng | |
| NO20065320L (no) | Imidazolderivater anvendt som tafiainhibitorer | |
| NO20070640L (no) | Forbedrede aprotininvananter | |
| DE602006008447D1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
| ATE553090T1 (de) | Cathepsincysteinproteasehemmer | |
| TR201907381T4 (tr) | Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |